The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behcet's disease: a systematic review and meta-analysis

被引：5

作者：

Mohammed, Reem Hamdy A. ^{[1
,3
]}

Woldeamanuel, Yohannes W. ^{[2
]}

机构：

[1] Cairo Univ, Sch Med, Dept Rheumatol & Rehabil, Cairo, Egypt

[2] Stanford Univ, Stanford Headache Ctr, Ctr Innovat Global Hlth, Dept Neurol & Neurol Sci,Sch Med, Stanford, CA USA

[3] Cairo Univ, Kasr Alainy Sch Med, Dept Rheumatol & Rehabil, Al Saray St, Cairo 11956, Egypt

来源：

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2023年 / 51卷 / 05期

关键词：

Neuro-Behcet's disease; anti-tumor necrosis factor therapy; refractory disease; magnetic resonance imaging; score for response; chimeric monoclonal antibody therapy; DAGGER-ETS DISEASE; EXTENSIVE TRANSVERSE MYELITIS; CASE SERIES; EFFICACY; MANAGEMENT; DIAGNOSIS;

D O I：

10.1177/03000605231169895

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

ObjectiveTo study the effectiveness of infliximab for the treatment of refractory central neuro-Behcet's disease. MethodsIn this systematic review and meta-analysis, the research question was designed using the 'Population, Intervention, Comparator, and Outcomes' (PICO) model and the search methodology was developed according to the PRISMA statement. The study was registered on PROSPERO. Web of Science, PubMed, and Cochrane Library databases were searched for articles published in English between January 2000 and January 2020. Data were analysed using Meta-Essentials software, version 10.12. Treatment effect size was determined by a random effects model. Interstudy heterogeneity was explored using I-2 statistics. Cumulative meta-analysis was conducted to assess the temporal trend for accumulating evidence. ResultsTwenty-one studies, comprising 64 patients (mean age, 38 .21 years and mean disease duration, 84.76 months) were included. Effect-size analysis showed that 93.7% of the treated patients in the analysis were responders to infliximab therapy (95% confidence interval 0.88, 0.993). There was no significant inter-study heterogeneity (I-2 = 0%). Cumulative analysis showed accumulating evidence favoring increasing effectiveness over the last 20 years. ConclusionInfliximab showed considerable therapeutic effectiveness in the treatment of refractory neuro-Behcet's disease.

引用

页数：22

共 35 条

[21] An attack of acute neuro-Beh‡et's disease during the course of chronic progressive neuro-Beh‡et's disease: report of two cases [J].

Matsui, Toshimichi ;

Ishida, Takashi ;

Tono, Toshihiro ;

Yoshida, Takuhiro ;

Sato, Shun-ichi ;

Hirohata, Shunsei .

MODERN RHEUMATOLOGY, 2010, 20 (06) :621-626

[22]

Moher D, 2009, ANN INTERN MED, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.07.299]

[23]

OHNO S, 1982, ARCH OPHTHALMOL-CHIC, V100, P1455

[24] Infliximab for the treatment of neuro-Behcet's disease: A case series and review of the literature [J].

Pipitone, Nicolo ;

Olivieri, Ignazio ;

Padula, Angela ;

D'Angelo, Salvatore ;

Nigro, Angelo ;

Zuccoli, Giulio ;

Boiardi, Luigi ;

Salvarani, Carlo .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (02) :285-290

[25] Efficacy of TNF a blockade in cyclophosphamide resistant neuro-Behcet disease [J].

Ribi, C ;

Sztajzel, R ;

Delavelle, J ;

Chizzolini, C .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (12) :1733-1735

[26] Utilization of the PICO framework to improve searching PubMed for clinical questions [J].

Schardt, Connie ;

Adams, Martha B. ;

Owens, Thomas ;

Keitz, Sheri ;

Fontelo, Paul .

BMC MEDICAL INFORMATICS AND DECISION MAKING, 2007, 7 (1)

[27]

SILMAN AJ, 1990, LANCET, V335, P1078

[28] ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions [J].

Sterne, Jonathan A. C. ;

Hernan, Miguel A. ;

Reeves, Barnaby C. ;

Savovic, Jelena ;

Berkman, Nancy D. ;

Viswanathan, Meera ;

Henry, David ;

Altman, Douglas G. ;

Ansari, Mohammed T. ;

Boutron, Isabelle ;

Carpenter, James R. ;

Chan, An-Wen ;

Churchill, Rachel ;

Deeks, Jonathan J. ;

Hrobjartsson, Asbjorn ;

Kirkham, Jamie ;

Juni, Peter ;

Loke, Yoon K. ;

Pigott, Theresa D. ;

Ramsay, Craig R. ;

Regidor, Deborah ;

Rothstein, Hannah R. ;

Sandhu, Lakhbir ;

Santaguida, Pasqualina L. ;

Schunemann, Holger J. ;

Shea, Beverly ;

Shrier, Ian ;

Tugwell, Peter ;

Turner, Lucy ;

Valentine, Jeffrey C. ;

Waddington, Hugh ;

Waters, Elizabeth ;

Wells, George A. ;

Whiting, Penny F. ;

Higgins, Julian P. T. .

BMJ-BRITISH MEDICAL JOURNAL, 2016, 355

[29] Atypical presentation of Beh‡et's disease with central nervous system involvement successfully treated with infliximab [J].

Studer, U. ;

Ruehe, B. ;

Waldegg, G. ;

Vajtai, I. ;

Escher, R. ;

Aeberli, D. .

RHEUMATOLOGY INTERNATIONAL, 2012, 32 (05) :1431-1435

[30] Introduction, comparison, and validation of Meta-Essentials: A free and simple tool for meta-analysis [J].

Suurmond, Robert ;

van Rhee, Henk ;

Hak, Tony .

RESEARCH SYNTHESIS METHODS, 2017, 8 (04) :537-553

← 1 2 3 4 →